A long-term clinical study of OPC-262 in patients with type 2 diabetes (Extension study from Study 262-09-001)

Otsuka Pharmaceutical Co., Ltd.0 个研究点目标入组 175 人开始时间: 2012年7月3日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Patients who completed Study 262-09-001 (patients who visited the hospital at visit Week 24)
•(2) Patients who are capable of giving informed consent prior to participating in this clinical study
•(3) Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner

•(1) Patients who withdrew fyom Study 262-09-001
•(2) Patients who experienced serious adverse events that the relationship with the study drug was not denied in Study 262-09-001
•(3) Patients who experienced serious adverse events that the relationship with the study drug are denied in Study 262-09-001 and whose symptoms are still emerged at the time of initiation of this study
•(4) Patients who met the exclusion criteria of Study 262-09-001 during the study period of Study 262-09-001
•(5) Female patients who wish to become pregnant during the study period of Study 262-09-002 or within 4 weeks after the study
•(6) Patients other wise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study

发起方